Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Following their discovery over 50 years ago, mesenchymal stromal cells (MSCs) have become one of the most studied cellular therapeutic products by both academia and industry due to their regenerative potential and immunomodulatory properties. The promise of MSCs as a therapeutic modality has been demonstrated by preclinical data yet has not translated to consistent, successful clinical trial results in humans. Despite the disparities across the field, MSC shareholders are unified under one common goal—to use MSCs as a therapeutic modality to improve the quality of life for those suffering from a malady in which the standard of care is suboptimal or no longer effective. Currently, there is no Food and Drug Administration (FDA)-approved MSC therapy on the market in the United States although several MSC products have been granted regulatory approval in other countries. In this review, we intend to identify hurdles that are impeding therapeutic progress and discuss strategies that may aid in accomplishing this universal goal of widespread therapeutic use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 1×
“We suggest that the ISCT follow the International Society for Extracellular Vesicles (ISEV) and the Functional Genomics Data Society (FGED) and establish their own unique set of minimally accepted publication criteria (Brazma et al., 2001; Théry et al., 2018).”
MethodKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 8×
“Hu et al. (2018) demonstrated that BM-MSCs from C57BL/6 mice expressed high levels of CD34 but lacked CD90 as well as noted slight strain differences in surface marker expression.”
BackgroundInfluentialBourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890 · cited 3×
“91, 1017–1026. Ludwig, N., Whiteside, T. L., and Reichert, T. E. (2019). Challenges in exosome isolation and analysis in health and disease.”
BackgroundMesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
Mechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436
Stolzing, A., Jones, E., McGonagle, D., & Scutt, A. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.12.002 · Cited by 1,195
Paracrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives
Liang, X., Ding, Y., Zhang, Y., Tse, H.-F., & Lian, Q. (2014) · Cell Transplantation · doi:10.3727/096368913x667709 · Cited by 909 · cited 1×
“Through the paracrine effect, MSCs can secrete biologically active molecules, such as cytokines, chemokines, growth factors, extracellular matrix, and extracellular vesicles (EVs) (Liang et al., 2014).”
BackgroundViswanathan, S., Shi, Y., Galipeau, J., Krampera, M., Leblanc, K., Martin, I., Nolta, J., Phinney, D. G., & Sensebe, L. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.08.002 · Cited by 839
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Cited by
A Brief Overview of Global Trends in MSC-Based Cell Therapy
Jovic, D., Yu, Y., Wang, D., Wang, K., Li, H., Xu, F., Liu, C., Liu, J., & Luo, Y. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10369-1 · Cited by 286
Prakash, N., Kim, J., Jeon, J., Kim, S., Arai, Y., Bello, A. B., Park, H., & Lee, S.-H. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00371-0 · Cited by 56
Kannan, S., Gokul Krishna, S., Gupta, P. K., & Kolkundkar, U. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-62544-8 · Cited by 39
“However, there was a reduced expression in the positive marker as per ISCT criteria 2 as the expression should be ≥ 95%, but this minimum criteria is heavily debated, with amendments suggested by many groups 29 .”
BackgroundTWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs
Lee, R. H., Boregowda, S. V., Shigemoto-Kuroda, T., Bae, E., Haga, C. L., Abbery, C. A., Bayless, K. J., Haskell, A., Gregory, C. A., Ortiz, L. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi2387 · Cited by 16
Controversies regarding transplantation of mesenchymal stem cells
Velikova, T., Dekova, T., & Miteva, D. G. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i2.90554 · Cited by 12
Metadata
- Authors
- Wright, A., Arthaud-Day, M. L., & Weiss, M. L.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-16
- Volume
- 9
- Pages
- 632717-632717
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3129996541
- Cited by
- 150
- References
- 18
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species. https://app.cochat.ai/papers/10.3389/fcell.2021.632717
- The paper
- Wright, A., Arthaud-Day, M. L., & Weiss, M. L. (2021). Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2021.632717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.